Rimonabant reduces the essential value of food in the genetically obese Zucker rat: An exponential demand analysis

Physiology and Behavior

Volumn 105, Issue 3, 2012, Pages 734-741

  Rasmussen, Erin B ^a   Reilly, William ^a   Buckley, Jessica ^a   Boomhower, Steven R ^a  

^a IDAHO STATE UNIVERSITY   (United States)

Author keywords

Behavioral economics; Essential value; Fixed ratio schedule; Obese Zucker rat; Rimonabant; Sucrose reinforcement

Indexed keywords

RIMONABANT; SUCROSE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FOOD INTAKE; LEAN BODY WEIGHT; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; REINFORCEMENT; ZUCKER RAT;

ANALYSIS OF VARIANCE; ANIMALS; CANNABINOIDS; CONDITIONING, OPERANT; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EATING; FEEDING BEHAVIOR; MALE; OBESITY; PIPERIDINES; PYRAZOLES; RATS; RATS, ZUCKER; REINFORCEMENT SCHEDULE;

EID: 80155125019     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2011.10.009     Document Type: Article

References (72)

1. Bickel W.K., Vuchinich R.E. Reframing health: behavioral change with behavioral economics 2000, Lawrence Erlbaum Associates, Mahwah, NJ.
2. Heather N., Vuchinich R.E. Choice, behavioural economics and addiction 2003, vol. 1. Elsevier Ltd, Kidlington, UK.
3. Epstein L.H., Leddy J.J., Temple J.L., Faith M.S. Food reinforcement and eating: a multilevel analysis. Psychol Bull 2007, 133(5):884-906.
4. Epstein L.H., Saelens B.E. Behavioral economics of obesity: food intake and energy expenditure. Reframing health: behavioral change with behavioral economics 2000, 293-311. Lawrence Erlbaum Associates, Mahwah, NJ. W.K. Bickel, R.E. Vuchinich (Eds.).
5. Rasmussen E.B., Reilly W., Hillman C. Demand for sucrose in lean and obese Zuckers. Behav Processes 2010, 85(2):191-197.
6. Atalayer D., Rowland N. Meal patterns of mice under systematically varying approach and unit costs for food in a closed economy. Physiol Behav 2009, 98:85-93.
7. Madden G.J., Smethells J.R., Ewan E.E., Hursh S.R. Tests of behavioral-economic assessments of relative reinforcer efficacy II: economic complements. J Exp Anal Behav 2007, 88(3):355-367.
8. Hursh S.R. Economic concepts for the analysis of behavior. J Exp Anal Behav 1980, 34:219-238.
9. Hursh S.R. Behavioral economics. J Exp Anal Behav 1984, 42:435-452.
10. Hursh S.R. Behavioral economic concepts and methods for studying health behavior. Reframing health: behavioral change with behavioral economics 2000, 27-60. Lawrence Erlbaum Associates, Mahwah, NJ. W.K. Bickel, R.E. Vuchinich (Eds.).
11. Hursh S.R., Raslear T.G., Shurtleff D., Bauman R., Simmons L. A cost-benefit analysis of demand for food. J Exp Anal Behav 1988, 50(3):419-440.
12. Duran C., McSweeney F.K. Rate of responding as a function of ratio requirement when no supplemental feedings are given. Behav Processes 1987, 15(2-3):293-303.
13. Hursh S.R., Silberberg A. Economic demand and essential value. Psychol Rev 2008, 115(1):186-198.
14. Drewnowski A., Grinker J.A. Temporal effects of delta-9-tetrahydrocannabinol on feeding patterns and activity of obese and lean Zucker rats. Behav Biol 1978, 23(1):112-117.
15. Williams C., Rogers P., Kirkham T. Hyperphagia in pre-fed rats following ordal delta-9 THC. Physiol Behav 1998, 65:343-346.
16. Williams C., Kirkham T. Anandamide induces overeating: mediation by central cannabinoid receptors. Psychopharmacology (Berl) 1999, 143(3):315-317.
17. Hao S., Avraham Y., Mechoulam R., Berry E.M. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet restricted mice. Eur J Pharmacol 2000, 392:147-156.
18. DiMarzo V., Goparaju S.K.I., Wang L., Liu J., Batkai S., Jarai Z., et al. Leptin regulated endocannabinoids are involved in maintaining food intake. Nature 2001, 410:822-825.
19. Kirkham T., Williams C. Endogenous cannabinoids and appetite. Nutr Res Rev 2001, 14:65-86.
20. Berry E., Mechoulam R. Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther 2002, 95(2):185-190.
21. Wakley A.A., Rasmussen E.B. Effects of cannabinoid drugs on the reinforcing properties of food in gestationally undernourished rats. Pharmacol Biochem Behav 2009, 94:30-36.
22. Gomez R., Navarro M., Ferrer B., Trigo J.M., Bilbao A., Del Arco I., et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002, 22(21):9612-9617.
23. Bergman J., Delatte M.S., Paronis C.A., Vemuri K., Thakur G.A., Makriyannis A. Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties. Physiol Behav 2008, 93(4-5):666-670.
24. Bermudez-Silva F., Viveros M.P., McPartland J.M., Rodriguez de Fonseca F. The endocannabinoid system, eating behavior, and energy homeostasis: the end or a new beginning?. Pharmacol Biochem Behav 2010, 95(4):375-382.
25. Droste S.M., Saland S.K., Schlitter E.K., Rodefer J.S. AM 251 differentially effects food-maintained responding depending on food palatability. Pharmacol Biochem Behav 2010, 95(4):443-448.
26. André A., Gonthier M. The endocannabinoid system: its roles in energy balance and potential as a target for obesity treatment. Int J Biochem Cell Biol 2010, 42(11):1788-1801.
27. Bellocchio L.C., Pasquali R., Pagotto U. The endocannabinoid system and energy metabolism. J Neuroendocrinol 2008, 20(6):850-857.
28. Colombo G., Agabio R., Diaz G., Lobina C., Reall R., Gessa G.L. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998, 63(8):PL113-PL117.
29. Simiand J., Keane M., Keane P.E., Soubrié P. SR141716, a CB1 cannabinoid antagonist, selectively reduces sweet food intake in the marmoset. Behav Pharmacol 1998, 9(2):179-181.
30. McLaughlin P.J., Winston K., Swezey L., Wisniecki A., Aberman J., Tardif D.J., et al. The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol 2003, 14(8):583-588.
31. Vickers S.P., Webster L.J., Wyatt A., Dourish C.T., Kennett G.A. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 2003, 167(1):103-111.
32. Thornton-Jones Z.D., Vickers S.P., Clifton P.G. The cannabinoid CB1 receptor antagonist SR141716A reduces appetitive and consummatory responses for food. Psychopharmacology (Berl) 2005, 179(2):452-460.
33. Carai M.A., Colombo G., Maccioni P., Gessa G.L. Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. CNS Drug Rev 2006, 12(2):91-99.
34. Gardner A., Mallet P.E. Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'. Eur J Pharmacol 2006, 530(1-2):103-106.
35. Herling A.W., Kilp S., Elvert R., Haschke G., Kramer W. Increased energy expenditure contributes more to the body weight reducing effect of rimonabant than reduced food intake in candy-fed Wistar rats. Endocrinology 2008, 149(5):2557-2566.
36. Rasmussen E.B., Huskinson S.L. Effects of rimonabant on behavior maintained by progressive ratio schedules of sucrose reinforcement in obese Zucker (fa/fa) rats. Behav Pharmacol 2008, 19(7):735-742.
37. Serrano A., Del Arco I., Javier Pavon F., Macias M., Perez-Valero V., Rodriguez de Fonseca F. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. Neuropharmacology 2008, 54(1):226-234.
38. Banerji M.A., Tiewala M. Rimonabant-the RIO North America trial: a new strategy to sustaining weight loss and related morbidity. Curr Diab Rep 2006, 6(3):228-229.
39. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006, 295(7):761-775.
40. Scheen A.J., Finer N., Hollander P., Jensen M.D., Van Gaal L.F. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006, 368(9548):1660-1672.
41. Despres J.P., Golay A., Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353(20):2121-2134.
42. Scheen A.J. CB1 Receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. J Neuroendocrinol 2008, 20:139-146.
43. Van Gaal L., Pi-Sunyer X., Despres J.P., McCarthy C., Scheen A. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 2008, 31:S229-S240.
44. Administration, U.F.a.D Testimony before FDA Advisory Committee of rimonabant. HRG Publication 2007, 1815.
45. Le Foll B., Gorelick D.A., Goldberg S.A. The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) 2009, 205(1):171-174.
46. DiPatrizio N.V., Simansky K.J. Activating parabrachial cannabinoid CB1 receptors selectively stimulates feeding of palatable foods in rats. J Neurosci 2008, 28:9702-9709.
47. Beardsley P.M., Thomas B.F., McMahon L.R. Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders. Int Rev Psychiatry 2009, 21(2):134-142.
48. Pagotto U., Vicennati V., Pasquali R. The endocannabinoid system and the treatment of obesity. Ann Med 2005, 37(4):270-275.
49. Drewnowski A., Grinker J.A. Food and water intake, meal patterns and activity of obese and lean Zucker rats following chronic and acute treatment with delta-9-tetrahydrocannabinol. Pharmacol Biochem Behav 1978, 9(5):619-630.
50. Yoshimatsu H., Machidori H., Doi T., Kurokawa M., Ookuma K., Kang M., et al. Abnormalities in obese Zuckers: defective control of histaminergic functions. Physiol Behav 1993, 54(3):487-491.
51. DiPatrizio N.V., Astarita G., Schwartz G., Xiaosong L., Piomelli D. Endocannabinoid signal in the gut controls dietary fat intake. Proc Natl Acad Sci U S A 2011, 108(31):12904-12908.
52. Mahler S.V., Smith K.S., Berridge K.C. Endocannabinoid hedonic hotspot for sensory pleasure: Anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward. Neuropsychopharmacology 2007, 32:2267-2278.
53. Wade-Galuska T., Galuska C., Winger G. Effects of daily morphine administration and deprivation on choice and demand for remifentanil and cocaine in rhesus monkey. J Exp Anal Behav 2011, 95:75-89.
54. Christensen C.J., Kohut S.J., Handler S., Silberberg A., Riley A.L. Demand for food and cocaine in Fischer and Lewis rats. Behav Neurosci 2009, 123(1):165-171.
55. Christensen C.J., Silberberg A., Hursh S.R., Roma P.G., Riley A.L. Demand for cocaine and food over time. Pharmacol Biochem Behav 2008, 91(2):209-216.
56. Kurtz T.W., Morris R.C., Pershadsingh H.A. The Zucker fatty rat as a genetic model of obesity and hypertension. Hypertension 1989, 13(6 Pt 2):896-901.
57. Siddiqui A.H., Ali Q., Hussain T. Protective role of angiotensin II subtype 2 receptor in blood pressure increase in obese Zucker rats. Hypertension 2009, 53(2):256-261.
58. Inokuchi J. Insulin resistance as a membrane microdomain disorder. Biol Pharm Bull 2006, 29(8):1532-1537.
59. Beck B. Neuropeptides and obesity. Nutrition 2000, 16(10):916-923.
60. Sahu A. Minireview: a hypothalamic role in energy balance with special emphasis on leptin. Endocrinology 2004, 145:2613-2620.
61. Thanos P.K., Ramalhete R.C., Michaelides M., Piyis Y.K., Wang G.J., Volkow N.D. Leptin receptor deficiency is associated with upregulation of cannabinoid 1 receptors in limbic brain regions. Synapse 2008, 62(9):637-642.
62. Smith S., Rasmussen E.B. Effects of 2-AG on the reinforcing properties of wheel activity in obese and lean Zucker rats. Behav Pharmacol 2010, 21:292-300.
63. Rasmussen EB, Hillman C. Rimonabant and naloxone reduce the reinforcing properties of exercise. Exp Clin Psychopharmacol 2011; in press.
64. Hodos W. Progressive ratio as a measure of reward strengh. Science 1961, 269:943-944.
65. Stafford D., LeSage M.G., Glowa J.R. Progressive-ratio schedules of drug delivery in the analysis of drug self-administration: a review. Psychopharmacology (Berl) 1998, 139(3):169-184.
66. Maccioni P., Pes D., Carai M.A., Gessa G.L., Colombo G. Suppression by the cannabinoid CB1 receptor antagonist, rimonabant, of the reinforcing and motivational properties of a chocolate-flavoured beverage in rats. Behav Pharmacol 2008, 19(3):197-209.
67. Foster T.M., Kinloch J., Poling A. The effects of session length on demand functions generated using FR schedules. J Exp Anal Behav 2011, 95:289-304. [68].
68. Houston A., McNamara J. The value of food: effects of open and closed economies. Anim Behav 1989, 37:546-562.
69. Collier G., Johnson D.F., Morgan C. The magnitude-of-reinforcement function in closed and open economies. J Exp Anal Behav 1992, 57(1):81-89.
70. Rowland N.E., Vaughan C.H., Mathes C.M., Mitra A. Feeding behavior, obesity, and neuroeconomics. Physiol Behav 2008, 93(1-2):97-109.
71. Järbe T.U., Andrzejewski M.E., DiPatrizio N.V. Interactions between the CB1 receptor agonist Delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited. Pharmacol Biochem Behav Nov 2002, 73(4):911-919.
72. Järbe T.U., DiPatrizio N.V., Li C., Makriyannis A. The cannabinoid receptor antagonist SR-141716 does not readily antagonize open-field effects induced by the cannabinoid receptor agonist (R)-methanandamide in rats. Pharmacol Biochem Behav Jul 2003, 75(4):809-821.